Galderma Group N (GALD SW) stock market data APIs
CHF146.2841
-1.29(-0.9%)
as of September 17, 2025
Try our APIs with
free plan!
Galderma Group N Financial Data Overview
Price chart is built with
Anychart
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Actinica, Dysport/Azzalure, Alluzience, Restylane and Restylane Skinboosters, Sculptra, Cetaphil and Alastin, Soolantra, Epiduo and Epiduo Forte, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Mirvaso, Nemluvio, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Prev. Close
146.2841
Open
144.9913
High
145.414
Low
144.9913
52 wk Range
72.5788-148.3
Market Cap
34 026 M
P/E Ratio
114.0945
Shares Outstanding
235 M
Revenue
4 690 M
EPS
0.55
Dividends (Yield)
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Galderma Group N (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galderma Group N data using free add-ons & libraries
Get Galderma Group N Fundamental Data
Galderma Group N Fundamental data includes:
- Net Revenue: 4 690 M
- EBITDA: 984 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-07-25
- EPS/Forecast: 1.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galderma Group N News
New
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
`` Aaron Farberg, MD, Dermatologist and Mohs Surgeon, Baylor Scott & White Health, United States, Member of the Galderma Global Sensitive Skincare Faculty `` `` Results from a real-world clinical st...
EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch
Galderma will present a wealth of data including new findings showing the impact of modern living on sensitive skin and insights from the largest global survey conducted on the condition Late-breaking...
Galderma Launches Alastin® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market
Galderma marks the 10th anniversary of its premium medical skincare brand Alastin with the launch of four core products in China, each formulated to support the skin’s natural regenerative abilities...
EQT completes sale of shares in Galderma Group AG
The sale resulted in aggregate gross proceeds of c. CHF 2.1 billion, of which EQT received c. CHF 555 million STOCKHOLM, July 31, 2025 /PRNewswire/ -- Further to previous announcements, an affiliate ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
